JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Adaptive Biotechnologies Corp

Closed

16.94 -0.99

Overview

Share price change

24h

Current

Min

16.77

Max

17.17

Key metrics

By Trading Economics

Income

4.2M

-26M

Sales

6.4M

59M

Profit margin

-43.467

Employees

619

EBITDA

11M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-7.08% downside

Dividends

By Dow Jones

Next Earnings

5 Nov 2025

Market Stats

By TradingEconomics

Market Cap

950M

2.6B

Previous open

17.93

Previous close

16.94

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Chart

Past performance is not a reliable indicator of future results.

Related News

28 Oct 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 Oct 2025, 23:25 UTC

Earnings

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 Oct 2025, 23:18 UTC

Earnings

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 Oct 2025, 22:20 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 Oct 2025, 22:13 UTC

Earnings

Wal-Mart de Mexico Net Profit Falls in 3Q

28 Oct 2025, 21:38 UTC

Earnings

Correction to Visa Sales Jump Article

28 Oct 2025, 21:17 UTC

Earnings

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 Oct 2025, 21:07 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- Update

28 Oct 2025, 21:02 UTC

Earnings

Mondelez Tempers Outlook as Costs Rise

28 Oct 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 Oct 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 Oct 2025, 23:02 UTC

Earnings

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 Oct 2025, 23:01 UTC

Earnings

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 Oct 2025, 22:46 UTC

Earnings

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 Oct 2025, 22:45 UTC

Earnings

SK Hynix 3Q Net KRW12.6T >000660.SE

28 Oct 2025, 22:44 UTC

Earnings

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 Oct 2025, 22:43 UTC

Earnings

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 Oct 2025, 22:42 UTC

Earnings

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 Oct 2025, 22:20 UTC

Earnings

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 Oct 2025, 22:02 UTC

Earnings

Review & Preview: Earnings Extravaganza -- Barrons.com

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 Oct 2025, 21:20 UTC

Earnings

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 Oct 2025, 21:19 UTC

Earnings

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 Oct 2025, 21:18 UTC

Earnings

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

-7.08% downside

12 Months Forecast

Average 16 USD  -7.08%

High 20 USD

Low 11 USD

Based on 8 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
help-icon Live chat